News Pfizer’s migraine push builds with Zavzpret nod Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.
News AbbVie files Qulipta for chronic migraine prevention AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
